$153.11
+1.17
(+0.77%)▲
Zoetis Inc is a global animal health company that produces and markets vaccines, medicines, and diagnostics for pets and livestock.
Insights on Zoetis Inc.
Revenue is up for the last 2 quarters, 2.15B → 2.21B (in $), with an average increase of 2.8% per quarter
Netprofit is down for the last 3 quarters, 671.0M → 525.0M (in $), with an average decrease of 11.6% per quarter
In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 45.9%
1.16%
Downside
Day's Volatility :1.51%
Upside
0.35%
3.02%
Downside
52 Weeks Volatility :26.3%
Upside
24.0%
Period | Zoetis Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -20.24% | -0.7% | 5.0% |
6 Months | -10.38% | 6.6% | 16.4% |
1 Year | -12.9% | 3.7% | 20.9% |
3 Years | -9.61% | 14.0% | 20.0% |
Market Capitalization | 68.5B |
Book Value | $10.9 |
Dividend Share | 1.5 |
Dividend Yield | 1.15% |
Earnings Per Share (EPS) | 5.08 |
PE Ratio | 29.48 |
PEG Ratio | 2.58 |
Wall Street Target Price | 223.49 |
Profit Margin | 27.43% |
Operating Margin TTM | 32.17% |
Return On Assets TTM | 13.15% |
Return On Equity TTM | 49.82% |
Revenue TTM | 8.5B |
Revenue Per Share TTM | 18.53 |
Quarterly Revenue Growth YOY | 8.5% |
Gross Profit TTM | 5.6B |
EBITDA | 3.5B |
Diluted Eps TTM | 5.08 |
Quarterly Earnings Growth YOY | 0.16 |
EPS Estimate Current Year | 5.8 |
EPS Estimate Next Year | 6.48 |
EPS Estimate Current Quarter | 1.32 |
EPS Estimate Next Quarter | 1.4 |
What analysts predicted
Upside of 45.97%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 5.8B | ↑ 9.76% |
Net Income | 1.4B | ↑ 65.28% |
Net Profit Margin | 24.52% | ↑ 8.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 6.3B | ↑ 7.47% |
Net Income | 1.5B | ↑ 5.04% |
Net Profit Margin | 23.96% | ↓ 0.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.7B | ↑ 6.63% |
Net Income | 1.6B | ↑ 9.2% |
Net Profit Margin | 24.54% | ↑ 0.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 7.8B | ↑ 16.49% |
Net Income | 2.0B | ↑ 24.36% |
Net Profit Margin | 26.2% | ↑ 1.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.1B | ↑ 3.91% |
Net Income | 2.1B | ↑ 3.78% |
Net Profit Margin | 26.16% | ↓ 0.04% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.5B | ↑ 5.74% |
Net Income | 2.3B | ↑ 10.88% |
Net Profit Margin | 27.43% | ↑ 1.27% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↓ 2.44% |
Net Income | 529.0M | ↑ 0.0% |
Net Profit Margin | 26.42% | ↑ 0.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 1.9% |
Net Income | 461.0M | ↓ 12.85% |
Net Profit Margin | 22.6% | ↓ 3.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↓ 1.96% |
Net Income | 552.0M | ↑ 19.74% |
Net Profit Margin | 27.6% | ↑ 5.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 9.0% |
Net Income | 671.0M | ↑ 21.56% |
Net Profit Margin | 30.78% | ↑ 3.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↓ 1.33% |
Net Income | 596.0M | ↓ 11.18% |
Net Profit Margin | 27.71% | ↓ 3.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 2.88% |
Net Income | 525.0M | ↓ 11.91% |
Net Profit Margin | 23.72% | ↓ 3.99% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↑ 25.52% |
Total Liabilities | 8.6B | ↑ 26.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | ↑ 7.13% |
Total Liabilities | 8.8B | ↑ 2.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 13.6B | ↑ 17.88% |
Total Liabilities | 9.8B | ↑ 11.3% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.9B | ↑ 2.14% |
Total Liabilities | 9.4B | ↓ 4.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 14.9B | ↑ 7.37% |
Total Liabilities | 10.5B | ↑ 12.46% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 14.3B | ↓ 4.28% |
Total Liabilities | 9.3B | ↓ 11.66% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 13.7B | ↓ 0.7% |
Total Liabilities | 9.0B | ↓ 1.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 14.9B | ↑ 9.15% |
Total Liabilities | 10.5B | ↑ 16.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.8B | ↓ 7.85% |
Total Liabilities | 9.3B | ↓ 11.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.7B | ↓ 0.04% |
Total Liabilities | 9.1B | ↓ 1.46% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.1B | ↑ 2.6% |
Total Liabilities | 9.0B | ↓ 1.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.3B | ↑ 1.28% |
Total Liabilities | 9.3B | ↑ 2.91% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 32.99% |
Investing Cash Flow | -2.3B | ↑ 736.67% |
Financing Cash Flow | 533.0M | ↓ 312.35% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 0.28% |
Investing Cash Flow | -504.0M | ↓ 77.69% |
Financing Cash Flow | -951.0M | ↓ 278.42% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 18.44% |
Investing Cash Flow | -572.0M | ↑ 13.49% |
Financing Cash Flow | 123.0M | ↓ 112.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↑ 4.09% |
Investing Cash Flow | -458.0M | ↓ 19.93% |
Financing Cash Flow | -1.9B | ↓ 1613.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 13.6% |
Investing Cash Flow | -883.0M | ↑ 92.79% |
Financing Cash Flow | -904.0M | ↓ 51.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 526.0M | ↑ 56.55% |
Investing Cash Flow | -124.0M | ↓ 38.92% |
Financing Cash Flow | -529.0M | ↓ 13.28% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 741.0M | ↑ 40.87% |
Investing Cash Flow | -438.0M | ↑ 253.23% |
Financing Cash Flow | 780.0M | ↓ 247.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 549.0M | ↓ 25.91% |
Investing Cash Flow | -216.0M | ↓ 50.68% |
Financing Cash Flow | -1.8B | ↓ 331.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 183.0M | ↓ 66.67% |
Investing Cash Flow | -80.0M | ↓ 62.96% |
Financing Cash Flow | -494.0M | ↓ 72.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 724.0M | ↑ 295.63% |
Investing Cash Flow | -567.0M | ↑ 608.75% |
Financing Cash Flow | -416.0M | ↓ 15.79% |
Sell
Neutral
Buy
Zoetis Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Zoetis Inc. | -10.98% | -10.38% | -12.9% | -9.61% | 53.43% |
Neurocrine Biosciences Inc. | -4.45% | 18.72% | 28.45% | 40.46% | 69.87% |
Haleon Plc Spon Ads | -0.12% | -1.82% | -7.31% | 9.45% | 9.45% |
Viatris Inc. | -5.61% | 18.46% | 12.35% | -16.23% | -32.07% |
Catalent, Inc. | 0.0% | 24.33% | 32.98% | -48.49% | 27.27% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Zoetis Inc. | 29.48 | 29.48 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Neurocrine Biosciences Inc. | 53.84 | 53.84 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.93 | 28.93 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Viatris Inc. | 222.4 | 222.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Zoetis Inc. | Buy | $68.5B | 53.43% | 29.48 | 27.43% |
Neurocrine Biosciences Inc. | Buy | $13.4B | 69.87% | 53.84 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 9.45% | 28.93 | 9.28% |
Viatris Inc. | Hold | $13.2B | -32.07% | 222.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 27.27% | 211.02 | -31.77% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
State Farm Mutual Automobile Ins Co
Capital Research & Mgmt Co - Division 3
T. Rowe Price Associates, Inc.
In the quarter ending March,2024. Zoetis Inc. has declared dividend of $0.43
Read MoreZoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Organization | Zoetis Inc. |
Employees | 14100 |
CEO | Ms. Kristin C. Peck |
Industry | Health Technology |
Targa Resources Corp.
$153.11
+0.77%
Sirius Xm Holdings Inc.
$153.11
+0.77%
Mbs Ishares
$153.11
+0.77%
Aspen Technology Inc
$153.11
+0.77%
Microstrategy Inc.
$153.11
+0.77%
Lowe's Companies Inc.
$153.11
+0.77%
Avantor Inc
$153.11
+0.77%
Cognizant Technology Solutions Corp.
$153.11
+0.77%
Consumer Staples Select Sector Spdr
$153.11
+0.77%